Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Melanoma 5Urinary Bladder Neoplasms 2Stomach Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Multiple Myeloma 1Microsatellite Instability 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1Hematologic Neoplasms 1Glioma 1Gastroesophageal Cancer 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

Cisplatin 10pembrolizumab 8Carboplatin 8durvalumab 5Pemetrexed 5Paclitaxel 51-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5osimertinib 4Specimen Handling 4Magnetic Resonance Spectroscopy 4Taxes 3Gemcitabine 3Bevacizumab 3cabozantinib 2atezolizumab 2Sunitinib 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiation 2Platinum 2Nivolumab 2Immunoglobulin G 2Docetaxel 2Disulfides 2CP protocol 2Biopsy 21,2-diaminocyclohexaneplatinum II citrate 2tremelimumab 1relatlimab 1peposertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma × relatlimab × Clear all
NCT05347212 2026-04-15

Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
Tumor-Agnostic

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡